Clinical trial · Observational
Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
EPREX (Epoetin Alfa) Versus ARANESP (Darbepoetin Alfa): Looking at Outcome of Anemia Treatment and Comparing Cost-effectiveness (EVALUATE).
NCT00264108CI-TRIAL-00014434completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the cost-effectiveness of epoetin alfa compared with darbepoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer. Epoetin alfa and darbepoetin alfa are genetically engineered proteins that stimulate red blood cell production.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Darbepoetin alfa | Drug | — | UNRESOLVED |
| Epoetin alfa | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- 1
- description
- Epoetin alfa 40 000 IU once weekly variable treatment length.
- interventionNames
- Drug: Epoetin alfa
- label
- 2
- description
- Darbepoetin alfa Either 150 ug once weekly or 500 ug once every 3 wks variable treatment length.
- interventionNames
- Drug: Darbepoetin alfa
Primary outcomes (1)
- measure
- Cost-effectiveness based on: cancer type and status, chemotherapy and other anti-cancer treatment, hemoglobin levels, use of either epoetin alfa or darbepoetin alfa, use of blood transfusions, serum iron levels and iron supplementation.
- timeFrame
- 4 weeks, 8 weeks and end of treatment
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a diagnosis of solid tumors, multiple myeloma (Kahlers' disease), non-Hodgkin lymphoma or Hodgkins' disease * Patients must already be receiving chemotherapy or start their first cycle within a week of enrollment * Patients must receive either epoetin alfa or darbepoetin alfa treatment (expected treatment duration is at least 4 weeks) Exclusion Criteria: * Patients not meeting all of the inclusion criteria for entry into the study * Patients who cannot read the Dutch language and/or do not understand the Dutch Informed Consent Form
References
Publications (0)
Data not yet available
No reference posted for this study.